Keywords: gsk, agrees, buy, sirtris, 720m, gain, foothold
GSK agrees to buy Sirtris for $720M to gain foothold in emerging field of sirtuins
Article | 28 April 2008
UK drug major GlaxoSmithKline has agreed to acquire Sirtris Pharmaceuticals for $720.0 million, bolstering its pipeline with the US biotechnology firm's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
